Immunovant Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $94.1M | $100.6M |
| FY2021 | — | $391.5M | $400.1M |
| FY2022 | — | $469.8M | $493.8M |
| FY2023 | — | $362.5M | $376.5M |
| FY2024 | — | $617.8M | $635.4M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $94.1M | $100.6M |
| FY2021 | — | $391.5M | $400.1M |
| FY2022 | — | $469.8M | $493.8M |
| FY2023 | — | $362.5M | $376.5M |
| FY2024 | — | $617.8M | $635.4M |